- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04959201
Combination of NMDA-enhancing and Antioxidant Treatments for Schizophrenia
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Several lines of evidence suggest that both NMDA and oxidative stress hypotheses have been implicated in schizophrenia. Previous studies found that some NMDA-enhancing agents were able to augment efficacy of antipsychotics in the treatment of schizophrenia. In addition, several drugs with antioxidant properties have been tested in clinical trials for the treatment of schizophrenia too. Whether a drug with antioxidant property can strengthen the efficacy of an NMDA-enhancer (NMDAE) in the treatment of schizophrenia remains unknown. Therefore, this study aims to compare NMDAE plus a drug with antioxidant property and NMDAE plus placebo in the treatment of schizophrenia. The subjects are the schizophrenia patients who remain symptomatic while having been stabilized with antipsychotic treatment. They keep their original treatment and are randomly, double-blindly assigned into two treatment groups for 12 weeks: (1) NMDAE plus Antioxidant agent (AO), or (2) NMDAE plus placebo. Clinical performances and side effects are measured at weeks 0, 2, 4, 6, 9, and 12. Cognitive functions are assessed at baseline and at endpoint of treatment by a battery of tests. The efficacies of NMDAE plus AO and NMDAE plus placebo will be compared.
Chi-square (or Fisher's exact test) will be used to compare differences of categorical variables and t-test (or Mann-Whitney test if the distribution is not normal) for continuous variables between treatment groups. Mean changes from baseline in repeated-measure assessments will be assessed using the generalized estimating equation (GEE). All p values for clinical measures will be based on two-tailed tests with a significance level of 0.05.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Hsien-Yuan Lane, M.D., Ph.D
- Phone Number: 1855 886 4 22052121
- Email: hylane@gmail.com
Study Locations
-
-
-
Taichung, Taiwan
- Recruiting
- Department of Psychiatry, China Medical University Hospital
-
Contact:
- Hsien-Yuan Lane, M.D., Ph.D
- Phone Number: 1855 886 4 22052121
- Email: hylane@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Have a DSM-5 (American Psychiatric Association) diagnosis of schizophrenia
- Remain symptomatic but without clinically significant fluctuation, while their antipsychotic doses are unchanged for at least 3 months and will be maintained during the period of the 12-week trial
- PANSS total score ≥ 60
- Agree to participate in the study and provide informed consent
Exclusion Criteria:
- DSM-5 diagnosis of intellectual disability or substance (including alcohol) use disorder
- History of epilepsy, head trauma, stroke, or serious medical or central nervous system diseases (other than schizophrenia) which may interfere with the study
- Clinically significant laboratory screening tests (including blood routine, biochemical tests)
- Pregnancy or lactation
- Inability to follow protocol
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: NMDAE plus Antioxidant agent (AO)
An NMDA enhancer plus a drug with antioxidant property
|
Use of an NMDA enhancer plus a drug with antioxidant property for the treatment of schizophrenia.
|
Placebo Comparator: NMDAE plus Placebo
An NMDA enhancer plus Placebo
|
Use of an NMDA enhancer plus placebo as a comparator.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change of Positive and Negative Syndrome Scale (PANSS)
Time Frame: week 0, 2, 4, 6, 9, 12
|
Assessment of overall symptoms.
Minimum value: 30, maximum value:210, the higher scores mean a worse outcome.
|
week 0, 2, 4, 6, 9, 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change of scales for the Assessment of Negative Symptoms (SANS) total score
Time Frame: week 0, 2, 4, 6, 9, 12
|
Assessment of negative symptoms.
Minimum value: 0, maximum value:100, the higher scores mean a worse outcome.
|
week 0, 2, 4, 6, 9, 12
|
Positive subscale of PANSS
Time Frame: week 0, 2, 4, 6, 9, 12
|
Assessment of positive symptoms.
Minimum value: 7, maximum value:49, the higher scores mean a worse outcome.
|
week 0, 2, 4, 6, 9, 12
|
Negative subscale of PANSS
Time Frame: week 0, 2, 4, 6, 9, 12
|
Assessment of negative symptoms.
Minimum value: 7, maximum value:49, the higher scores mean a worse outcome.
|
week 0, 2, 4, 6, 9, 12
|
General Psychopathology subscale of PANSS
Time Frame: week 0, 2, 4, 6, 9, 12
|
Assessment of general psychopathology.
Minimum value: 16, maximum value:112, the higher scores mean a worse outcome.
|
week 0, 2, 4, 6, 9, 12
|
Clinical Global Impression
Time Frame: week 0, 2, 4, 6, 9, 12
|
Assessment of general impression.
Minimum value: 1, maximum value:7, the higher scores mean a worse outcome.
|
week 0, 2, 4, 6, 9, 12
|
Global Assessment of Functioning
Time Frame: week 0, 2, 4, 6, 9, 12
|
Assessment of social, occupational, and psychological function.
Minimum value: 1, maximum value:100, the higher scores mean better function.
|
week 0, 2, 4, 6, 9, 12
|
Hamilton Rating Scale for Depression
Time Frame: week 0, 2, 4, 6, 9, 12
|
Assessment of depressive symptoms.
Minimum value: 0, maximum value:52, the higher scores mean a worse outcome
|
week 0, 2, 4, 6, 9, 12
|
Quality of Life Scale
Time Frame: week 0, 2, 4, 6, 9, 12
|
Assessment of life quality.
Minimum value: 0, maximum value:126, the higher scores mean a better outcome.
|
week 0, 2, 4, 6, 9, 12
|
Cognitive function
Time Frame: Week 0, 12
|
Ten tests for assessment of 7 cognitive domains:
All tests have no unit. Firstly, for the domain (a. and c.) with more than one test, a composite T score will be calculated by standardizing the average of each T score (with a mean of 50 and a SD of 10 for making every test comparative). Secondly, a global composite score (for all seven domains) and a neurocognitive composite score (for the first 6 domains, a-f) will be also calculated by standardizing the average of the T score of each domain (Lane HY et al, JAMA Psychiatry. 2013). |
Week 0, 12
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CMUH108-REC1-177
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Bradley LegaRecruiting
-
All India Institute of Medical Sciences, BhubaneswarRecruitingTreatment Resistant SchizophreniaIndia
-
King's College LondonSouth London and Maudsley NHS Foundation TrustRecruitingTreatment-resistant Schizophrenia | Healthy Controls | Treatment-responsive SchizophreniaUnited Kingdom
-
University of Sao PauloUnknownRefractory Schizophrenia | Super Refractory SchizophreniaBrazil
-
Ohio State UniversityRecruitingTreatment-resistant SchizophreniaUnited States
-
University Hospital, BrestRecruitingSchizophrenia | Schizophrenia Prodromal | Schizophrenia, ChildhoodFrance
-
NYU Langone HealthNot yet recruitingTreatment-resistant SchizophreniaUnited States
-
Johns Hopkins UniversityNational Institute of Mental Health (NIMH)RecruitingTreatment-resistant SchizophreniaUnited States
Clinical Trials on NMDAE plus AO
-
China Medical University HospitalNational Health Research Institutes, TaiwanRecruiting
-
China Medical University HospitalMinistry of Science and Technology, TaiwanRecruitingSchizophreniaTaiwan
-
University of TriesteCompletedParkinson Disease
-
China Medical University HospitalNational Health Research Institutes, TaiwanRecruiting
-
China Medical University HospitalRecruiting
-
China Medical University HospitalNational Science and Technology Council, TaiwanRecruiting
-
China Medical University HospitalNational Science and Technology CouncilRecruiting
-
Hospital Cruz Roja MexicanaUnknown
-
ActiveO Inc.CompletedDisk, HerniatedCanada
-
TherOxCompletedMyocardial InfarctionUnited States